Clinical trials: Clostridium Difficile Infection, open to volunteers
Clostridioides Difficile Infection
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18 years of age and above.
- Trial name
- PRISM (NCT07285213)
- Testing
- AZD5148
- Where
- 117 sites in United States, Australia and 12 more
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Crohn Disease, Ulcerative Colitis
Safety and Efficacy of Fecal Microbiota Transplantation
The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease…
- Conditions
- Crohn Disease, Ulcerative Colitis, Celiac Disease, Irritable Bowel Syndrome
- Trial name
- NCT04014413
- Testing
- Fecal Microbiota Transplantation
- Where
- Hong Kong
- Volunteers
- 450 people
- Sponsor
- Chinese University of Hong Kong
Clostridioides Difficile Infection
Lifestyle and Recurrent Clostridioides Difficile Infection (CDI)
This study aims to evaluate the impact of diet on the gut microbiome in adults with Clostridioides difficile infection (CDI). Eligible participants will be randomized and receive meals plus different types of health counseling.
- Trial name
- NCT07613645
- Testing
- Health counseling sessions, Diet (control diet), Diet (experimental diet)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan
Clostridium Difficile Infections
Clostridioides Difficile Infection: Analyzing CLInic Evolution and Bacterial Clearance
Clostridioides difficile (formerly Clostridium) is a bacterium found in the form of spores (resistance form) in the environment to which patients may be exposed.
- Trial name
- DECLIC (NCT06030245)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Recurrent Clostridioides Difficile Infection, Colonic Surgery
Intestinal Microbiota Transplantation in Patients Undergoing Colon Resection
This is a single-center, open-label study for safety and feasibility of IMT in patients undergoing colonic surgery. After consent, individuals of the ages of 18-75 with a history of diverticulitis or sigmoid colon cancer will be…
- Trial name
- NCT06370884
- Testing
- IMT
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Minnesota
Clostridium Difficile Infection
A Safety Trial to Evaluate an Orally Ingested Yeast Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile
This is a Phase 1, first-in-human, double-blind, placebo-controlled, adaptive-design, single-site study, involving dose exploration cohorts.
- Trial name
- NCT07649096
- Testing
- FZ002
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Clostridioides Difficile Infection
Long-Term Outcomes After CDI: FMT Versus Antibiotic-Only Treatment
The goal of this observational study is to learn about the long-term effects of fecal microbiota transplantation (FMT) compared with antibiotic-only treatment in adults who were treated for Clostridioides difficile infection…
- Trial name
- LTO-CDI (NCT07569380)
- Where
- Sweden
- Volunteers
- 250 people
- Sponsor
- Umeå University
Clostridium Difficile Infection, Vancomycin Resistant Enterococci Infection
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
The goal of this clinical trial is to determine if oral vancomycin can prevent C.diff infection in adults who are critically ill and are at high risk of C.diff infection due to their medical conditions and being in the hospital.
- Trial name
- NCT07221370
- Testing
- Vancomycin 125mg
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- Riverside University Health System Medical Center
Inflammatory Bowel Diseases, Clostridioides Difficile Infection
Xylitol Use for Decolonization of C. Difficile in Patients With IBD
This is a randomized, placebo-controlled, dose-ranging study to assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in IBD patients.
- Trial name
- NCT05852587
- Testing
- Xylitol
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Brigham and Women's Hospital
Clostridium Difficile, Ulcerative Colitis
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
Clostridioides difficile infection (CDI) is the most frequent cause of infectious diarrhea in hospitalized patients and is responsible for 20-30 % of antibiotic-associated diarrhea cases.
- Trial name
- NCT06071312
- Testing
- single FMT, sequential FMT
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
C. Difficile, C. Difficile Infection
Clostridioides Difficile Controlled Human Infection Model
This study will investigate in healthy study subjects, the safety and tolerability of a controlled infection with Clostridioides difficile, a gut bacterium that can cause diarrhoea.
- Conditions
- C. Difficile, C. Difficile Infection, Controlled Human Infection
- Trial name
- CloDiCHI (NCT06702345)
- Testing
- encapsulated 10^4 CFU toxigenic. C. difficile spores, Vancomycin, Clindamycin
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Irritable Bowel Syndrome, Diarrhea-Predominant (IBS-D), Recurrent Clostridioides Difficile Infection (rCDI)
A Flexible Clinical Trial to Test if Freeze-dried Fecal Microbiota Therapy Helps Treat Diarrhea-predominant Irritable Bowel Syndrome or Prevent Recurring C. Difficile Infections.
The goal of this clinical trial is to learn if oral lyophilized fecal microbiota therapy (ORAL-LYO-FMT) helps treat diarrhea-predominant irritable bowel syndrome (IBS-D) and prevent the recurrence of Clostridioides difficile…
- Conditions
- Irritable Bowel Syndrome, Diarrhea-Predominant (IBS-D), Recurrent Clostridioides Difficile Infection (rCDI), Fecal Microbiota Therapy (FMT), Irritable Bowel Syndrome (IBS)
- Trial name
- ORAL-LYO-FMT (NCT06948461)
- Testing
- ORAL-LYO-FMT
- Volunteers
- 63 people
- Sponsor
- PharmaPlanter Technologies Inc
Clostridioides Difficile Infection
Study of Clostridioides Difficile in Infants
Clostridioides difficile infection (CDI) poses an increasing threat to infant and young child health, with detection rates rising annually.
- Trial name
- NCT06788769
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Westlake University
Clostridioides Difficile Infection
Washed Microbiota Transplantation for Clostridioides Difficile Infection
This is a real-world study to explore the safety and the efficacy of washed microbiota transplantation （WMT） for patients with Clostridioides Difficile Infection （CDI）.
- Trial name
- NCT06106698
- Testing
- WMT
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence
STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection
The STOP-CDI study is a multicenter, randomized, open-label, three-arm clinical trial comparing the efficacy of fecal microbiota transplantation (FMT) preceded by vancomycin, fidaxomicin monotherapy, and standard-of-care…
- Conditions
- Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Fecal Microbiota Transplantation (FMT), Comparative Effectiveness of CDI Treatments
- Trial name
- STOP-CDI (NCT07120490)
- Testing
- FMT (fecal microbiota transplantation), Fidaxomicin, Vancomycin (VAN) treatment
- Volunteers
- 424 people
- Sponsor
- Medical University of Warsaw
Clostridioides Difficile Infection, Recurrent Infection
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
Clostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea in Europe, with over 120,000 cases and almost 3,700 deaths per year.
- Trial name
- LIVEDIFF (NCT06306014)
- Testing
- EXL01
- Where
- 10 sites in France
- Volunteers
- 56 people
- Sponsor
- Hospices Civils de Lyon
Clostridioides Difficile Infection
Epidemiology of Clostridioides Difficile Infection (CDI) in Long-term Care Facilities, Assessment of Professional Practices Related to CDI Risk Prevention, and Strategies for Improving Care.
Clostridioides difficile infection (CDI) is the leading cause of infectious diarrhea among older adults. The epidemiology of community-acquired CDI, particularly among residents of long-term care facilities, remains poorly…
- Trial name
- EpiCE (NCT07920627)
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Clostridioides Difficile Infection
Clostridioides Difficile: Understanding Responses and Treatment Effects
The goal of this observational study is to learn how different treatments for Clostridioides difficile infection (CDI) work, and which biological mechanisms are involved in recovery.
- Trial name
- CURE-CDI (NCT07374094)
- Testing
- Antibiotic treatment, Fecal microbiota transplantation (FMT)
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Umeå University
Clostridioides Difficile Infection, Clostridium Difficile Infection
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
This is a randomized, double-blind, placebo-controlled trial to determine the optimal dose and safety of oral alanyl-glutamine between 4, 24, and 44 g doses administered for 10 days with standard therapy among first time incident…
- Conditions
- Clostridioides Difficile Infection, Clostridium Difficile Infection, Clostridium Difficile Diarrhea, Clostridia Difficile Colitis
- Trial name
- ACT (NCT04305769)
- Testing
- Alanyl-glutamine
- Where
- 2 sites in United States
- Volunteers
- 260 people
- Sponsor
- University of Virginia
Clostridia Difficile Colitis
Vancomycin Taper to Prevent Recurrent Clostridioides Difficile
Indirect evidence from network meta-analyses of randomized controlled trials (RCTs) suggest that a pulse and taper (P-T) of vancomycin may be non-inferior to 10-days of fidaxomicin for the prevention of recurrent Clostridioides…
- Trial name
- TAPER-V2 (NCT07328971)
- Testing
- Fidaxomicin, Vancomycin capsule
- Where
- 2 sites in Canada
- Volunteers
- 500 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre